Moreover, clinical studies and trials are essential to assess the diagnostic and therapeutic value of FTO and m6A methylation in ovarian cancer, with the ultimate goal of developing more effective and personalized treatment strategies for patients (Figure 8). The gene discussed is FTO; the disease is ovarian cancer.